Loading data for NPCE — first visit, this takes a few seconds.

NeuroPace, Inc. (NPCE)

NasdaqGM: NPCE · 即時價格 · USD

14.90

+0.15 (1.02%)

收盤價： Sep 04, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	10.16
市值	511M
營收 (ttm)	107M
淨利（ttm）	-16.2M
	1.95
	-0.47
	n/a
	-67.06
P/B (ttm)	42.94
P/S (ttm)	4.78
財報日期	Nov 3, 2026

賣價	17.12
成交量	92,320
20 日平均成交量	186,785
開盤價	14.62
前收盤價	14.75
當日區間	14.47 - 14.90
52 週範圍	9.22 - 19.60
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the co...

[閱讀更多]

產業 Medical Devices

類股 Healthcare

IPO 日期 Apr 22, 2021

員工 220

證券交易所 NasdaqGM

股票代號 NPCE

網站 https://www.neuropace.com

完整的公司簡介

財務表現

NeuroPace 在 2025 年的營收為 99.99M，較前一年的 79.91M 增加 25.13%。淨利為 -21.47M，較前期減少 -20.91%。

財務報表

財報驚奇

NeuroPace 已於 Aug 11, 2026 公布季度財報：

營收為 $22.83M 低於預期 $0, 年增 17.05% 成長.
每股盈餘為 -0.18 超出預期 0.01, 年增 14.29% 成長.

下次財報發布

NeuroPace, Inc. 的下次財報預計於 Nov 3, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

4 天前 · Zacks

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

2 週前 · GuruFocus.com

NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...

NeuroPace Inc (NPCE) raises full-year guidance on 21.3% RNS revenue growth, while navigating an unexpected FDA request for additional IGE data.

3 週前 · Zacks

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

3 週前 · Zacks

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

3 週前 · Zacks

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

第 1 頁，共 2 頁

NeuroPace, Inc. (NPCE)